CredoScientia - Bibliothèque

Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review.

BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor (ICI)-based therapy has achieved impressive success in various cancer types. Several ICIs have been unprecedentedly approved as the treatment regi…

Thérapies de Conversion

Wang, H., Qian, Y. W., Dong, H., & Cong, W. M. (2024). Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review.. Hepatobiliary Surg Nutr, 13(3), 472-493. https://doi.org/10.21037/hbsn-22-527

01/06/2024 Lire →

A commentary on 'Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study'.

Thérapies de Conversion

Zhao, X., Gao, F., & Lei, Z. (2024). A commentary on 'Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study'.. Int J Surg, 110(6), 3990-3991. https://doi.org/10.1097/JS9.0000000000001299

01/06/2024 Lire →

Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis.

Hepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the opportunity to undergo radical …

Thérapies de Conversion

Li, S., Zhang, Z., Wang, Z., Wang, K., Sui, M., Liu, D., & Liang, K. (2024). Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis.. Oncol Lett, 27(6), 265. https://doi.org/10.3892/ol.2024.14398

01/06/2024 Lire →

Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.

INTRODUCTION: The incidence of primary liver cancer (PLC) has experienced a significant global increase, primarily attributed to the rise in hepatocellular carcinoma (HCC). Unfortunately, HCC is often…

Thérapies de Conversion

Zhu, S., Yu, Y., Yang, M., Liu, X., Lai, M., Zhong, J., Zhao, X., Lu, L., & Liu, Y. (2024). Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.. Expert Rev Anticancer Ther, 24(6), 423-434. https://doi.org/10.1080/14737140.2024.2346624

01/06/2024 Lire →

Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study.

BACKGROUND: Patients with peritoneal metastasis (PM) from gastric cancer (GC) exhibit poor prognosis. Chemoimmunotherapy offers promising clinical benefits; however, its efficacy and predictive biomar…

Thérapies de Conversion

Yu, P., Ding, G., Huang, X., Wang, C., Fang, J., Huang, L., Ye, Z., Xu, Q., Wu, X., Yan, J., Ou, Q., Du, Y., & Cheng, X. (2024). Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study.. Int J Surg, 110(6), 3504-3517. https://doi.org/10.1097/JS9.0000000000001281

01/06/2024 Lire →

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.

BACKGROUND: To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable …

Thérapies de Conversion

Kikuchi, T., Takeuchi, Y., Nouso, K., Kariyama, K., Kuwaki, K., Toshimori, J., Iwado, S., Moriya, A., Hagihara, H., Takabatake, H., Tada, T., Yasunaka, T., Sakata, M., Sue, M., Miyake, N., Adachi, T., Wada, N., Onishi, H., Shiraha, H., … Otsuka, M. (2024). Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.. Liver Int, 44(6), 1456-1463. https://doi.org/10.1111/liv.15907

01/06/2024 Lire →

Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome.

A 44-year-old woman with Lynch syndrome was referred to our hospital for treatment of recurrence of microsatellite instability-high rectal cancer. [F]Fluorodeoxyglucose (18FDG)-positron emission tomog…

Thérapies de Conversion

Matsumoto, A., Shimada, Y., Nakano, M., Ozeki, H., Yamai, D., Murata, M., Ishizaki, F., Nyuzuki, H., Ikeuchi, T., & Wakai, T. (2024). Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome.. Clin J Gastroenterol, 17(3), 451-456. https://doi.org/10.1007/s12328-024-01931-0

01/06/2024 Lire →

Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.

BACKGROUND: Conversion therapy for initially unresectable hepatocellular carcinoma (iuHCC) using lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus a PD-1 inhibitor (LTP) ha…

Thérapies de Conversion

Li, X., Wang, X., Bai, T., Chen, J., Lu, S., Wei, T., Tang, Z., Zhao, G., Lu, H., Li, L., & Wu, F. (2024). Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.. Dig Liver Dis, 56(6), 1078-1086. https://doi.org/10.1016/j.dld.2023.11.027

01/06/2024 Lire →

Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.

BACKGROUND: The preoperative conversion therapy for advanced hepatocellular carcinoma (HCC) is still being explored. This study reported the potential of combination of transarterial chemoembolization…

Thérapies de Conversion

Zhao, W., Liu, C., Wu, Y., Yao, Z., Dou, Q., Li, W., Zhao, X., & Xia, N. (2024). Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.. Transl Cancer Res, 13(5), 2315-2331. https://doi.org/10.21037/tcr-24-93

31/05/2024 Lire →

Downstaging strategies for unresectable hepatocellular carcinoma.

A significant number of patients with hepatocellular carcinoma (HCC) are usually diagnosed in advanced stages, that leads to inability to achieve cure. Palliative options are focusing on downstaging a…

Thérapies de Conversion

Karachaliou, G. S., Dimitrokallis, N., & Moris, D. P. (2024). Downstaging strategies for unresectable hepatocellular carcinoma.. World J Gastroenterol, 30(20), 2731-2733. https://doi.org/10.3748/wjg.v30.i20.2731

28/05/2024 Lire →

Options and survival benefits of conversion therapy for unresectable hepatocellular carcinoma.

In the study by Wu , patients with unresectable hepatocellular carcinoma were subjected to transarterial chemoembolization (TACE) as a conversion therapy in order to render their tumors suitable for r…

Thérapies de Conversion

She, W. H., & Cheung, T. T. (2024). Options and survival benefits of conversion therapy for unresectable hepatocellular carcinoma.. World J Gastroenterol, 30(18), 2479-2481. https://doi.org/10.3748/wjg.v30.i18.2479

14/05/2024 Lire →

Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study.

OBJECTIVE: The objective of this study is to evaluate and compare the survival benefit and safety of surgery following conversion therapy versus surgery alone in patients diagnosed with surgically res…

Thérapies de Conversion

Ma, Z., Xiao, Z., Yin, P., Wen, K., Wang, W., Yan, Y., Lin, Z., Li, Z., Wang, H., Zhang, J., & Mao, K. (2024). Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study.. Int J Surg, 110(5), 2910-2921. https://doi.org/10.1097/JS9.0000000000001193

01/05/2024 Lire →